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Summary 
Objectives 
About 5-10% of patients with asthma suffer from poorly-controlled disease despite 
corticosteroid (CS) therapy, which may indicate the presence of CS insensitivity. We 
determined whether relative CS insensitivity is present in alveolar macrophages 
(AMs) from severe asthma patients and its association with p38 mitogen-activated 
protein kinase (MAPK) activation and MAPK phosphatase-1 (MKP-1).  
Methods 
Fiberoptic bronchoscopy and bronchoalveolar lavage (BAL) were performed in 19 
severe and 20 non-severe asthma patients, and for comparison, in 14 normal 
volunteers. AMs were exposed to lipopolysaccharide (LPS, 10 g/ml) and 
dexamethasone (10-8 and 10-6M). Supernatants were assayed for cytokines using an 
ELISA-based method. p38 MAPK activity and MKP-1 messenger RNA (mRNA) 
expression were assayed in cell extracts.  
Results 
The inhibition of LPS-induced IL-1, IL-6, IL-8, MCP-1 and MIP-1 release by 
dexamethasone (10-6M) was significantly less in AMs from severe asthma compared 
to AMs from non-severe asthma. There was increased p38 MAPK activation in AMs 
from severe asthma patients. MKP-1 expression induced by dexamethasone and 
LPS, expressed as a ratio of LPS-induced expression, was reduced in severe 
asthma. 
Conclusion  
AMs from patients with severe asthma demonstrate corticosteroid insensitivity 
associated with increased p38 MAPK activation that may result from impaired 
inducibility of MKP-1.  
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INTRODUCTION  
Although most asthma patients suffer from mild-to-moderate disease that 
responds to inhaled corticosteroids (CS), a minority of patients have severe disease 
characterised by asthma symptoms and exacerbations that are largely unresponsive 
to treatment including systemic CS (1). Despite the advent and use of efficacious 
inhaled CS and long-acting -agonists as combination therapy, many patients with 
asthma do not achieve reasonable control of their asthma (2). These patients 
consume a more significant proportion of medical resources in terms of use of drugs, 
admissions to hospital or use of emergency services, and time off work or school 
(3;4). Definitions of severe asthma or therapy-resistant asthma have been proposed 
by working groups of the European Respiratory and American Thoracic Societies (5) 
(6), and the clinical features of recently-described cohorts (7-9) attest to the persistent 
loss of control of asthma despite the optimal use of  asthma medication.  
An important aspect of severe asthma is the relative reduction in 
effectiveness of CS in controlling asthma. In asthmatics, who have been defined as 
being corticosteroid-resistant as defined by a response  of <15% of baseline FEV1 
after taking prednisolone (30-40 mg/day) over 14 days while demonstrating marked 
bronchodilator response to inhaled 2-agonists (10), a reduction in the suppressive 
effect of dexamethasone on the proliferative response of or release of a neutrophil 
activating factor from peripheral blood mononuclear cells (PBMCs) has been 
observed compared to cells from CS-responsive asthmatics who have a >25% 
improvement in FEV1 after prednisolone (11;12). However, these CS-resistant 
asthmatics are not similar in clinical presentation or in asthma severity as patients 
with severe asthma.  
The macrophage is an important immune and inflammatory effector cell in 
asthma, and is a potential source of many pro-inflammatory mediators. The alveolar or 
airway macrophage is in a greater state of activation in patients with asthma compared 
to that from non-asthmatic individuals (13-15). The alveolar macrophage (AM) may 
also be an important site of action of CS since inhaled CS therapy  causes a reduction 
in the ability of AMs of patients with mild-to-moderate asthma to release 
proinflammatory cytokines (14). In a recent investigation, we showed that PBMCs 
obtained from severe asthma patients demonstrated diminished CS suppression of IL-
1, IL-8 and MIP-1 release relative to PBMCs from non-severe asthma patients(16).  
In the current work, we determined whether AMs also show similar 
corticosteroid insensitivity in severe asthma. In order to determine the activation status 
of AMs, we assayed the  activity of p38 mitogen-activated protein kinase (MAPK) 
which is responsive to environmental stresses including heat, osmotic shock, 
inflammatory cytokines and lipopolysaccharide (LPS) (17). In addition, p38 MAPK is 
known to regulate the production of  many cytokine proinflammatory cytokines such as 
IL-8 and GM-CSF from AMs (18;19), and overreactivity of p38 MAPK has been 
associated with CS resistance in PBMCs induced by a combination of IL-4 and IL-13 
(20). MAPK phosphatase-1 (MKP-1) dephosphorylates and inactivates MAPKs, 
including p38 MAPK (21), and we therefore also measured the expression of MKP-1 in 
the macrophages from patients with severe asthma. 
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METHODS  
Study participants 
Patients with severe and non-severe asthma were recruited amongst the cohorts of 
patients referred to and attending our Asthma Clinic. Asthma patients demonstrated 
either  an improvement in FEV1 after inhaling 400 g of salbutamol from a metered-
dose inhaler of  ≥12% of baseline forced expiratory volume in one sec (FEV1) or 
bronchial hyperresponsiveness with a PC20 of <16 mg/ml. Current and ex-smokers 
of >5 pack-years were excluded. Severe asthmatics (n=20) were defined according to 
the American Thoracic Society major criteria of either continuous or near-continuous 
oral CS or high dose inhaled CS or both in order to achieve a level of mild-moderate 
persistent asthma, and by the presence of 2 or more minor criteria of asthma control 
(6). These patients underwent a protocol during which the diagnosis of asthma was 
confirmed, the severity assessed and therapeutic issues were optimised including 
adherence to therapy, potential aggravating factors assessed and co-morbidity issues 
evaluated and treated as required (7).  
 Non-severe asthmatic patients (n=19) were those that did not fall into the 
severe asthma category and who used 0-2,000 µg of inhaled beclomethasone or 
equivalent dosage per day with perfect control of their asthma. In order to see how 
the responses of these asthmatic patients compared to those of non-asthmatic 
subjects, healthy volunteers (n=14; 2 female; 37.6±2.4 years; FEV1 %predicted= 98% 
±5.0) with no history of asthma, on no medication and who had never smoked were 
recruited.  
The study protocol was approved by the National Heart and Lung Institute and 
Royal Brompton Hospital Ethics Committee. All volunteers gave written informed 
consent to participate in the study. 
Fiberoptic bronchoscopy 
The entry criteria for performing bronchoscopies in patients with severe asthma 
comprised of (i) an  FEV1 ≥ 45% predicted prior to and FEV1 ≥ 55 % predicted 
following bronchodilators (ii) less than 6 asthma exacerbations in the previous 6 
months to bronchoscopy (iii)  no asthma hospitalization within 6 months; (iv) no 
endotracheal intubation for asthma within 1 year; and (v) regular daily oral dose of < 
20 mg of prednisolone.  
Fibreoptic bronchoscopy was performed using topical anaesthesia with 
lignocaine to the upper and lower airways and with intravenous midazolam (3-6 mg) 
and alfentanyl (125 g).  Warmed 0.9% NaCl solution was instilled (50 ml x 4) in right 
middle lobe and broncho-alveolar lavage (BAL) fluid was recovered by gentle suction.  
Alveolar Macrophage Isolation 
Washed BAL cells were suspended in culture media (RPMI with 0.5% fetal calf 
serum, antibiotics and L-glutamine) and counted on a haemocytometer. Cytospins 
were stained with Diff Quick  stain (Harleco, Gibbstown, NJ) for differential cell counts. 
Macrophages were purified by adhesion to the plastic well for 4 hours and then 
exposed for 18 hours to LPS (10 μg/ml) in the presence or absence of 
dexamethasone (10-8 or 10
-6
 M). LPS at 10 g/ml was the submaximal stimulatory 
concentration in terms of release of IL-8.   
Cytokine release 
Macrophage supernatants were mixed with microsphere beads (Beadlyte®, Upstate 
Technology, NY) coated with capture antibodies to ten cytokines: MCP-1, MIP-1, 
RANTES, TNF, IL-1, IL-8, INF- -6, IL-10 and GM-CSF. Biotinylated reporter 
antibodies were added to bind the microsphere bead-cytokine complexes. Finally, a 
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fluorophore, streptavidin-phycoerythrin was added to bind the biotinylated reporter 
thus emitting a fluorescent signal, that is measured in a Luminex® 100 laser 
spectrophotometer (Luminex Corporation, Austin, TX). Microsphere beads for each 
cytokine emitted a unique ratio of two other fluorophores. Cytokine concentrations 
were derived from mean fluorescence intensity standard curves.  
p38 MAPK phosphorylation 
To determine p38 MAPK activity, additional macrophages from a subset of 10 non-
severe and 10 severe patients were stimulated with LPS 10 μg/ml for 30 minutes in 
the presence or absence of dexamethasone (10
-6
 M) and were scraped. These 
studies were possible in patients in whom the recovery of macrophages was 
sufficient. The contents of each well were stored in radioimmunoprecipitation lysis 
buffer at -70ºC for later assay. Maximal p38 MAPK activation occurred at 30 min. 
Samples were assayed for phosphorylated and total p38 MAK kinase by enzyme 
immunoassay (Titerzyme, Cambridge Bioscience, UK), using rabbit polyclonal 
antibodies to phospho-p38 and to total p38.  
Real-time reverse transcription-polymerase chain reaction (RT-PCR)  for MKP-1 
Macrophages after 24 hours of incubation with LPS or with LPS and dexamethasone 
from the last 7 non-severe and 6 severe asthma patients enrolled were used. Total 
RNA extracts were prepared using RNAqueous-Micro kit (Ambion). Contaminating 
genomic DNA was digested with DNase I treatment, DNAse was removed by 
vortexing with DNAse inactivation resin. The RNA was transferred to an RNAse-free 
tube and stored at – 20oC.  Complementary DNA (cDNA) for real-time quantitative 
PCR analysis was  synthesised from 500 ng total RNA using random hexamer 
primers and AMV reverse transcriptase (Promega, Madison, WI).  Real-time PCR 
were performed using the Rotor Gene 3000 (Corbett Research) with PCR 
amplifications performed in a 20  μl reaction volume using the SYBR Green Master 
Mix Reagent Kit (Promega). Cycling parameters were 95°C for 15 min, followed by 
annealing and extension at 45 cycles of 94°C for 15s, 60°C for 25s and 72°C for 25s. 
To control for variation within the procedure, a reference mRNA, 18s rRNA, was also 
measured. Oligonucleotide primer sequences, MKP-1: forward, 5’-
GTACATCAAGTCCATCTGAC-3’; reverse, 5’-GGTTCTTCTAGGAGTAGACA-3’; 18s 
rRNA: forward, 5’-CTTAGAGGGACAAGTGGCG-3’; reverse, 5’-
ACGCTGAGCCAGTCAGTGTA-3’. 
 
Data analysis 
Results were expressed as mean ± SEM. The main statistical analysis pertained to 
examination of differences between non-severe and severe asthma patients. 
Differences in concentrations for each cytokine released from AMs caused by LPS 
and by LPS plus dexamethasone were calculated and ranked, and a multivariate 
analysis of variance was performed to determine differences between severe and 
non-severe asthma. Baseline data between severe asthma and non-severe asthma 
patients were compared using the Mann-Whitney U test. Correlations were 
determined using Spearman rank  correlation coefficient. A p value of < 0.05 was 
taken as significant.  
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RESULTS 
Patient characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Characteristics of non-severe and severe asthma  
 
Abbreviations: BAL: bronchoalveolar lavage; F = female; M =male; eNO= exhaled nitric 
oxide levels in parts per billion (ppb); FEV1=forced expiratory volume in one second; FVC= 
forced vital capacity; PC20= provocative concentration of methacholine causing a 20% fall 
in FEV1; BDP: beclomethasone dipropionate; ND not determined. Values represent mean 
± SEM.   
1Atopy defined as positive skin prick tests to one or more common aeroallergens. 
2Measured as per cent increase in FEV1 after 400g salbutamol aerosol.  
*p<0.05; **p≤0.01; ***p≤0.001 compared to non-severe 
 
 
Ten severe asthma patients were on oral prednisolone (5-40 mg/day) and 9 of 
the non-severe asthma patients were not on ICS. Severe asthmatics had more airflow 
obstruction with a lower FEV1 (p<0.001), greater bronchial hyperresponsiveness 
(p<0.05) and a greater bronchodilator reversibility (p<0.01) (Table 1). BAL fluid from 
severe asthmatics showed a greater percentage of  
neutrophils (p<0.009) and a smaller percentage of macrophages (p<0.008) than that 
from non-severe asthmatics (Table 1).  
 Non-severe asthma Severe asthma 
Gender (F:M) 8:12 14:6 
Age (years) 40.0± 2.4 41.4 ±2.6 
Duration of 
asthma (years) 
27.4± 3.2 27.3± 2.6 
Atopy1 19/20 18/20 
FEV1 (% 
predicted) 
84.9± 3.0 59.9± 4.7*** 
FVC (% predicted) 93.9± 3.7 72.9± 4.9*** 
FEV1/FVC ratio 74.6 ±2.1 66.9± 2.4* 
Bronchodilator 
response2 
9.5 ±1.8 20.9 ±3.9** 
Log PC20 (mg/ml) 0.19± 0.14 -0.48± 0.17**  
Prednisolone 
dose (mg/day) 
0 11.8 ± 13.7*** 
BDP equivalent 
(g/day) 
526± 167 2530± 292*** 
BAL cells   
Total cell count (x 
106) 
7.32 ± 0.87 5.76 ± 0.68 
Macrophage (%) 97.1 ± 0.84 93.2 ± 1.11** 
Lymphocyte (%) 1.27 ± 0.34 2.56 ± 0.63 
Neutrophils (%) 0.98 ± 0.29 2.58 ± 0.5** 
Eosinophils (%) 0.63 ± 0.29 1.73 ± 0.65 
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  The bronchoscopic procedure was well-tolerated by all subjects. Two of the 20 
severe asthmatics who underwent bronchoscopy developed an asthma exacerbation 
requiring systemic corticosteroids and extended hospital stay beyond 24 hours. Both 
responded fully to standard asthma therapy.  
 
LPS-stimulated cytokine release  
Baseline release of GM-CSF, IFN-, IL-10, and IL-1 was close to the limit of 
detection while for the other six cytokines, levels did not differ between severe and 
non-severe asthmatics (Fig 1A). Baseline release of the cytokines was higher than 
the release observed in each of the 2 asthmatic groups. LPS-stimulated cytokine 
release was also similar between severe and non-severe asthmatics, except for IL-8 
release which was greater from macrophages of non-severe asthmatics (Fig 1B). 
 
Corticosteroid suppression of cytokine release  
To quantify the degree of sensitivity of AM to dexamethasone, the release of each 
cytokine following dexamethasone together with LPS-stimulation was expressed as a 
percentage of the cytokine release following LPS-stimulation (Fig 2). In general, there 
was lesser suppression of cytokine release by dexamethasone 10-6 M (Fig 2A) in 
macrophages from severe asthmatics compared to non-severe asthmatics. Using a  
multivariate analysis of variance  to analyse the suppressed level of each cytokine by 
dexamethasone (10-6 M), statistical significance was reached for IL-1β (p=0.05), IL-6 
(p<0.01),  IL-8 (p<0.01), MCP-1 (p<0.05) and MIP-1α (p=0.01). In general, the degree 
of suppression of cytokine release from macrophages of normal subjects appeared 
similar to that of the non-severe asthmatic group, apart from IL-8.  There was no 
difference in dexamethasone sensitivity between AMs of severe and non-severe 
asthmatics  at 10-8 M (Fig 2B), apart from IFN which was less suppressible in AMs 
from patients with severe asthma (p<0.05). 
 
LPS-induced p38 phosphorylation  
p38 MAPK phosphorylation, measured as the ratio of phosphorylated p38 to 
total p38, was increased in AMs of non-severe and asevere asthma patients by LPS, 
but not in Ams from normal subjects (Fig 3A). the baseline p38 MAPK activity of 
unstimulated AMs were not significantly different between the groups. When 
expressed as a ratio of p38 phosphorylation after LPS to unstimulated levels, there 
was significantly higher activation in AMs from non-severe asthmatics and severe 
asthmatics compared to those from normal subjects (p<0.05 and p<0.01 respectively; 
Fig 3B); however, there was greater activation in the severe asthmatics compared to 
non-severe asthmatics (p<0.05).  
When the data from the 2 asthmatic groups were combined, LPS-induced p38 
MAPK phosphorylation correlated directly with the degree of steroid insensitivity of 
cytokine release for IL-1β (p<0.05), IL-6 (p<0.05), IL-8 (p<0.05) and MIP-1α (p<0.01) 
(Fig 4). There was no significant correlation for any of the 4 cytokines within the non-
severe asthma group; however, within the severe group, there was significant 
correlation for IL-1 (rho= 0.76; p=0.037) and IL-6 (rho=0.7; p=0.043). 
 
Induction of MAPK phosphatase-1 (MKP-1) by LPS and dexamethasone 
Induction of MKP-1 gene expression, as measured by mRNA abundance,  in AMs 
stimulated with dexamethasone and LPS was higher than in cells  stimulated with 
LPS alone in normal and in non-severe asthmatic subjects (p<0.01 and p<0.05 
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respectively). However, such an increase in MKP-1 mRNA  abundance was not 
observed in AMs from severe asthmatics. Baseline transcript levels of MKP-1 were 
not significantly different between the 3 groups. MKP-1 mRNA expression following 
co-treatment with  dexamethasone and  LPS, compared to that induced by LPS 
alone, was significantly higher in non-severe asthmatics than in severe asthmatics 
(p<0.05; Fig 5).  
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DISCUSSION 
            AMs from patients with severe asthma patients demonstrate impaired CS 
suppression of release of several inflammatory cytokines (IL-1, IL-6, IL-8, MCP-1 
and MIP-1) stimulated by LPS, compared to AMs from non-severe asthmatics. CS 
sensitivity of AMs from non-severe asthmatics paralleled that of AMs from non-
asthmatic subjects. The differences between severe and non-severe asthmatics 
were present at dexamethasone 10-6M and not at 10-8M indicating a reduction in 
maximal CS response of the former group. Our results are therefore similar to those 
we previously reported in peripheral blood mononuclear cells obtained from patients 
with severe asthma(16). In the current study, we examined the possibility that the 
decrease in CS sensitivity of the AMs in severe asthma was related to an increased 
activation of p38 MAPK phosphorylation. We found that p38 MAPK activation was 
increased in the severe asthma group compared to the non-severe asthma and 
normal groups. Furthermore, the degree of CS insensitivity was correlated with the 
degree of p38 MAPK activation, providing support for p38 MAPK activation being a 
potential determinant of CS responsiveness. 
Although there was increased activation of p38 MAPK in AMs from patients 
with severe asthma, we did not find any increase in cytokine release induced by LPS 
in these patients. In addition, there was only a relatively small difference in 
inflammatory markers between the 2 groups, with a significant increase in 
neutrophils in bronchoalveolar lavage fluid from patients with severe asthma, despite 
these patients being treated with higher doses of inhaled CS and despite 50% of 
these patients also taking a daily dose of prednisolone. This may be a reflection of 
the relative reduction of CS sensitivity observed in patients with severe asthma. It 
was the effect of dexamethasone in inhibiting cytokine release that was impaired, an 
observation that was associated with relative MKP-1 underexpression induced by 
dexamethasone. This indicates that there may be a defect in MKP-1 expression, 
which is known to be induced by CS (22), that may allow for excessive p38 MAPK 
activity.  Macrophage cell lines transfected with MKP-1 show an accelerated 
inactivation of p38 MAPK (23) and murine alveolar macrophages treated with the 
MKP-1 inhibitor, triptolide, show prolonged p38 activity (24).  Similarly, 
dexamethasone-mediated suppression of the proinflammatory cytokines, TNF and 
IL-1, was impaired in macrophages from MKP-1 knock-out mice, indicating that the 
expression of MKP-1 was required for inhibition of these cytokines by 
dexamethasone(25).  The inability of CS to upregulate MKP-1 activity in severe 
asthma could be a mechanism by which CS insensitivity occurs since some of the 
biological effects of CS may occur through inactivation of MAPK kinases (26).  
However, the non-asthmatic macrophages also demonstrated a reduction in MKP-1 
expression in the presence of dexamethasone, although to a lesser extent when 
compared to macrophages from non-asthmatic subjects, indicating that the 
asthmatic state is also associated with an inability of MKP-1 upregulation. However, 
given the small number of asthmatic samples examined, the data on MKP-1 should 
be considered preliminary and needs to be confirmed in larger studies.  
The fact that patients with severe asthma still have uncontrolled asthma despite 
taking high doses of inhaled CS, sometimes together with oral CS, has led to the 
hypothesis that patients with severe asthma are relatively resistant to the therapeutic 
effect of CS. Such patients are not absolutely resistant to the effects of CS since stopping 
CS therapy usually leads to a worsening of asthma in these patients. Rather, such 
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patients, often labelled as corticosteroid-dependent asthma, have a partial impaired 
response to CS. This current work on AMs activation studied ex-vivo provides some 
support for this concept. Recent cohorts of patients with severe asthma have revealed 
that  these patients show daily symptoms and increased use of reliever medication, 
increased urgent health care utilisation with recurrent exacerbations of asthma, and a 
substantial proportion of patients on a regular oral dose of prednisolone (27;28). Patients 
with severe asthma recruited to the current study showed a greater degree of airflow 
obstruction, greater bronchodilator response to salbutamol, and had a greater degree of 
methacholine airway responsiveness compared to non-severe asthma patients, all 
indicators of severity of asthma. However, in terms of inflammation, there was only a 
small increase of 2.5-fold in BAL neutrophils. Airway neutrophilia has been recognised as 
a feature of severe asthma (29;30), although this could be a reflection of oral 
corticosteroid therapy(31).  One might indeed impute the reduced CS sensitivity in 
patients with severe asthma to the continuous use of CS, particularly oral CS, that could 
lead to down-regulation of the CS receptor expression and translocation. However, we 
found no differences in dexamethasone suppression of AM function from severe 
asthmatics on inhaled CS alone  and those on inhaled and oral CS therapy. Similarly, 
there were no differences in AM sensitivity from non-severe asthma patients on inhaled 
CS, and those not taking inhaled CS. 
            We have previously shown that IL-2 and IL-4 exposure of blood monocytes  
caused a reduction in CS ligand binding affinity due to phosphorylation of the 
glucocorticoid receptor (GR), that could be reversed by a p38 MAPK inhibitor (20), or 
by an indirect effect on the ligand binding domain of GR (32).  p38 MAPK activation 
may also lead to phosphorylation and phosphoacetylation of histones at the 
promoter regions of NF-B dependent genes such as those activated by LPS 
resulting in enhanced recruitment of the transcription factor NF-B (19;33). This is 
consistent with our previous observation that  histone deacetylase (HDAC) activity is 
reduced in PBMCs and alveolar macrophages of asthmatic patients(16;34). p38 
MAPK activation may be involved in the stabilisation and increased translation of 
pro-inflammatory cytokine mRNA, dependent on the conserved AU-rich elements in 
the 3’-UTR region (35), particularly of. IL-1β, IL-6, IL-8, and MIP-1α (36-38). These 
potential downstream effects of p38 MAPK may lead to a reduction in the 
effectiveness of dexamethasone. 
         In summary, alveolar macrophages from severe asthma patients demonstrate 
relative CS insensitivity compared to those of non-severe asthma patients. Increased 
p38 MAPK activation may underlie the insensitivity but further work will be needed to 
directly implicate p38 MAPK activation in the CS insensitivity of severe asthma. 
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LEGEND TO FIGURES 
 
Figure 1. Concentrations of ten cytokines measured in cell culture supernatants of 
unstimulated alveolar macrophages (Panel A) and of alveolar macrophages 
stimulated with lipopolysaccharide 10 μg/ml (Panel B) from normal volunteers, non-
severe asthmatics and severe asthmatics. Data shown as median and interquartile 
range. 
Figure 2. Effect of dexamethasone 10-6 M (panel A) and 10-8 M (panel B) on the 
suppression of release of ten cytokines from alveolar macrophages stimulated by 
lipopolysaccharide (10μg/ml). Data is expressed as cytokine release after 
dexamethasone and lipopolysaccharide (LPS) as a % of release after LPS alone. 
Data shown as median and interquartile range. 
Figure 3.  Panel A. p38 MAPK phosphorylation measured as the ratio of 
phosphorylated p38 to total p38 at baseline (unstim) and following stimulation  by 
lipopolysaccharide (LPS; 10 μg/ml) in alveolar macrophages from normal subjects 
and severe and non-severe asthmatics. Panel B. Similar data expressed as fold-
increase in p38 MAPK phosphorylation after LPS compared to baseline.  Horizontal 
bars are the median values. 
Figure 4. Correlation between relative steroid suppression of IL-1, IL-6, IL-8 and 
MIP-1 release and the increase of p38 phosphorylation induced by LPS in alveolar 
macrophages of patients with asthma. ●: severe asthma, ○: non-severe asthma. 
Figure 5. Induction of MAPK phosphatase-1 (MKP-1) mRNA expression measured 
by quantitative RT-PCR. Panel A shows effect of LPS and of combination of 
lipopolysaccharide (LPS) and dexamethasone  (Dex, 10-6M), and panel B the ratio of 
expression after LPS and dexamethasone to that after LPS alone in alveolar 
macrophages from normal volunteers, and non-severe and severe asthma patients.  
Horizontal bars are median values. 
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Figure 3   
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Figure 4 
-0.5 0.0 0.5 1.0 1.5
0
25
50
75
100
r=0.48
p<0.05
Log increase in p38 phosphorylation
following LPS stimulation
%
 c
y
to
k
in
e
 r
e
le
a
s
e
 w
it
h
 L
P
S
 &
 D
e
x
re
la
ti
v
e
 t
o
 L
P
S
 a
lo
n
e
IL-1
-0.5 0.0 0.5 1.0 1.5
0
25
50
75
100
r=0.57
p<0.05
IL-6
Log increase in p38 phosphorylation
following LPS stimulation
%
 c
y
to
k
in
e
 r
e
le
a
s
e
w
it
h
 L
P
S
 &
 D
e
x
re
la
ti
v
e
 t
o
 L
P
S
 a
lo
n
e
-0.5 0.0 0.5 1.0 1.5
0
25
50
75
100
r=0.54
p<0.05
IL-8
Log increase in p38 phosphorylation
following LPS stimulation
%
 c
y
to
k
in
e
 r
e
le
a
s
e
w
it
h
 L
P
S
 &
 D
e
x
re
la
ti
v
e
 t
o
 L
P
S
 a
lo
n
e
-0.5 0.0 0.5 1.0 1.5
0
25
50
75
100
r=0.7
p<0.01
MIP-1
Log increase in p38 phosphorylation
following LPS stimulation
%
 c
y
to
k
in
e
 r
e
le
a
s
e
 w
it
h
 L
P
S
 &
 D
e
x
re
la
ti
v
e
 t
o
 L
P
S
 a
lo
n
e
 21 
 Figure 5  
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